Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. variatect

variaTECT SIGNED

A novel genetic assay for risk assessment of cognitive decline in Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 variaTECT project word cloud

Explore the words cloud of the variaTECT project. It provides you a very rough idea of what is the project "variaTECT" about.

solutions    detection    2050    emission    complete    fast    unresolved    figure    trials    snp    patient    probability    beta    fluid    extracted    saliva    innovation    deployment    lumbar    double    strategy    dysfunction    stratify    ivd    positron    variatect    plan    collected    disorder    alzheimer    risk    initiated    cytox    dementia    generate    csf    cerebrospinal    triple    snpfitr    130k    snps    progressively    scans    platform    supply    leads    score    clinical    market    single    provides    degeneration    disease    device    brain    cognitive    2030    population    85    processed    vitro    types    proprietary    broad    nucleotide    chain    tomography    worldwide    individuals    upgrade    accuracy    people    amyloid    puncture    revenues    software    blood    pieces    snpfitrtm    multiple    plasma    living    drafted    genetic    dna    polymorphism    accurate    almost    aging    diagnostic    46m    10m    primary    array    feasibility    person    capacity    healthcare    mark    subjects    save    labs    ce    pet    10k    ad    tests    prevalent    obtain    data   

Project "variaTECT" data sheet

The following table provides information about the project.

Coordinator		 CYTOX LIMITED 

Organization address
address: 53 FOUNTAIN STREET
city: MANCHESTER
postcode: M2 2AN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Project website http://www.cytoxgroup.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOX LIMITED UK (MANCHESTER) coordinator 50˙000.00

Map

 Project objective

Alzheimer’s Disease (AD) is the most prevalent cognitive disorder and progressively leads to complete brain dysfunction and degeneration. The number of people living with Alzheimer’s worldwide is now estimated at 46M, with this figure set to almost double by 2030 and more than triple by 2050 due to population aging. Current methods for early assessment of AD are based on detection of β-amyloid in the brain Positron Emission Tomography (PET) scans, blood plasma tests or in cerebrospinal fluid (CSF) (via lumbar puncture). However, these solutions present some unresolved issues for broad market deployment. Cytox has developed the variaTECT platform to stratify AD risk in individuals by using a fast, accurate, reliable and cost-effective way to generate specific genetic information. The variaTECT comprises a proprietary 130K single nucleotide polymorphism (SNP) variaTECT array and the proprietary SNPfitRTM software to analyse data generated from the array. DNA extracted from a patient’s blood or saliva sample is collected and analyzed on the variaTECT array. The primary genetic data are then processed by the SNPfitR software, which provides a risk score associated with the probability to develop AD. variaTECT has an 85% accuracy, it can save up to €10k person-year for the healthcare systems and it can generate new revenues (up to €10M) for genetic labs. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, Cytox will upgrade the array design to increase the number of SNPs and the SNPfitR software to stratify subjects into different dementia types. Production capacity will be increased up to 100,000 pieces per year. Multiple clinical trials will be then initiated to obtain CE mark as In-Vitro Diagnostic (IVD) device.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VARIATECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VARIATECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More